NBIX
Neurocrine Biosciences, Inc. NASDAQ Listed May 23, 1996$149.56
Mkt Cap $15.0B
52w Low $115.66
76.1% of range
52w High $160.18
50d MA $130.82
200d MA $137.42
P/E (TTM)
27.4x
EV/EBITDA
20.7x
P/B
4.0x
Debt/Equity
0.1x
ROE
14.7%
P/FCF
18.8x
RSI (14)
—
ATR (14)
—
Beta
0.35
50d MA
$130.82
200d MA
$137.42
Avg Volume
1.2M
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
12780 El Camino Real · San Diego, CA 92130 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 1.68 | 1.97 | +17.3% | 135.06 | +10.3% | +8.9% | +1.7% | — | — | — | — |
| Feb 11, 2026 | AMC | 1.80 | 1.88 | +4.4% | 137.44 | -3.7% | -10.4% | +0.8% | +2.9% | +0.5% | +1.3% | — |
| Oct 28, 2025 | AMC | 1.58 | 2.04 | +29.1% | 147.38 | -5.0% | -6.4% | +0.0% | +3.7% | -0.9% | +0.9% | — |
| Jul 30, 2025 | AMC | 0.98 | 1.06 | +8.2% | 136.76 | +0.2% | -6.2% | +0.5% | -0.7% | +0.3% | +0.0% | — |
| May 5, 2025 | AMC | 0.54 | 0.08 | -85.0% | 109.75 | +12.1% | +8.4% | +2.3% | -3.4% | -1.5% | +4.1% | — |
| Feb 6, 2025 | AMC | 1.62 | 1.00 | -38.3% | 150.51 | -16.3% | -18.5% | -3.1% | -1.6% | +0.3% | -0.3% | — |
| Oct 30, 2024 | AMC | 1.51 | 1.24 | -17.9% | 124.33 | -1.5% | -3.3% | +1.6% | -1.4% | +0.8% | +3.1% | — |
| Aug 1, 2024 | AMC | 1.05 | 0.63 | -40.0% | 153.15 | -0.7% | -0.0% | -3.6% | -1.4% | -1.0% | +1.8% | — |
| May 1, 2024 | AMC | 1.01 | 0.42 | -58.4% | 143.03 | +0.5% | -2.2% | +0.6% | +0.7% | +1.0% | -2.9% | — |
| Feb 7, 2024 | AMC | 1.15 | 1.44 | +25.2% | 136.29 | +0.4% | -1.4% | -1.6% | -1.4% | +2.6% | -1.5% | — |
| Oct 31, 2023 | AMC | 0.97 | 0.82 | -15.5% | 110.94 | -0.0% | +0.5% | +1.7% | -0.8% | +1.4% | +2.3% | — |
| Aug 1, 2023 | AMC | 0.78 | 0.95 | +21.8% | 103.44 | +0.2% | +0.7% | -0.8% | -1.6% | -0.4% | -0.1% | — |
| May 3, 2023 | AMC | 0.26 | -0.79 | -403.8% | 98.62 | +0.2% | -2.8% | +1.6% | +0.5% | -0.7% | -0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | Leerink Partners | Maintains | Outperform → Outperform | — | $130.22 | $131.25 | +0.8% | +0.7% | -0.8% | -1.9% | +0.3% | +0.1% |
| Apr 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $131.64 | $132.02 | +0.3% | -2.1% | -2.0% | +3.6% | +0.5% | -2.3% |
| Apr 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $132.48 | $133.35 | +0.7% | -1.2% | +1.7% | -1.1% | -2.1% | -2.0% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $132.48 | $133.35 | +0.7% | -1.2% | +1.7% | -1.1% | -2.1% | -2.0% |
| Apr 7 | Wedbush | Maintains | Outperform → Outperform | — | $132.48 | $133.35 | +0.7% | -1.2% | +1.7% | -1.1% | -2.1% | -2.0% |
| Apr 7 | Citigroup | Maintains | Buy → Buy | — | $132.48 | $133.35 | +0.7% | -1.2% | +1.7% | -1.1% | -2.1% | -2.0% |
| Apr 6 | Needham | Maintains | Buy → Buy | — | $131.60 | $130.93 | -0.5% | +0.7% | -1.2% | +1.7% | -1.1% | -2.1% |
| Mar 12 | JP Morgan | Maintains | Overweight → Overweight | — | $129.54 | $129.51 | -0.0% | -1.4% | +1.6% | +0.1% | +0.7% | +0.0% |
| Feb 17 | JP Morgan | Maintains | Overweight → Overweight | — | $124.12 | $125.14 | +0.8% | +2.9% | +0.5% | +1.3% | -1.1% | -0.2% |
| Feb 17 | Truist | Maintains | Buy → Buy | — | $124.12 | $125.14 | +0.8% | +2.9% | +0.5% | +1.3% | -1.1% | -0.2% |
| Feb 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $123.10 | $123.83 | +0.6% | +0.8% | +2.9% | +0.5% | +1.3% | -1.1% |
| Feb 12 | BMO Capital | Maintains | Market Perform → Market Perform | — | $137.44 | $132.34 | -3.7% | -10.4% | +0.8% | +2.9% | +0.5% | +1.3% |
| Feb 12 | Citigroup | Maintains | Buy → Buy | — | $137.44 | $132.34 | -3.7% | -10.4% | +0.8% | +2.9% | +0.5% | +1.3% |
| Feb 12 | Needham | Maintains | Buy → Buy | — | $137.44 | $132.34 | -3.7% | -10.4% | +0.8% | +2.9% | +0.5% | +1.3% |
| Feb 12 | RBC Capital | Maintains | Outperform → Outperform | — | $137.44 | $132.34 | -3.7% | -10.4% | +0.8% | +2.9% | +0.5% | +1.3% |
| Feb 12 | Wedbush | Maintains | Outperform → Outperform | — | $137.44 | $132.34 | -3.7% | -10.4% | +0.8% | +2.9% | +0.5% | +1.3% |
| Feb 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $137.44 | $132.34 | -3.7% | -10.4% | +0.8% | +2.9% | +0.5% | +1.3% |
| Jan 23 | UBS | Maintains | Buy → Buy | — | $137.37 | $138.16 | +0.6% | -0.9% | -1.2% | -0.5% | +0.6% | +2.5% |
| Jan 12 | JP Morgan | Maintains | Overweight → Overweight | — | $135.79 | $135.21 | -0.4% | -2.3% | -0.3% | +2.3% | -1.5% | -0.7% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $140.62 | $139.54 | -0.8% | -3.6% | +0.2% | -2.3% | -0.3% | +2.3% |
| Jan 8 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $140.62 | $139.54 | -0.8% | -3.6% | +0.2% | -2.3% | -0.3% | +2.3% |
| Dec 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $148.74 | $150.47 | +1.2% | -4.7% | +0.1% | +2.2% | +1.7% | -0.2% |
| Dec 12 | Mizuho | Maintains | Neutral → Neutral | — | $154.75 | $155.00 | +0.2% | -1.3% | +0.8% | -3.5% | -4.7% | +0.1% |
| Dec 11 | Stifel | Maintains | Buy → Buy | — | $155.63 | $153.39 | -1.4% | -0.6% | -1.3% | +0.8% | -3.5% | -4.7% |
| Dec 8 | RBC Capital | Maintains | Outperform → Outperform | — | $155.51 | $156.65 | +0.7% | -0.3% | +0.0% | +0.4% | -0.6% | -1.3% |
| Dec 5 | TD Cowen | Maintains | Buy → Buy | — | $154.22 | $154.47 | +0.2% | +0.8% | -0.3% | +0.0% | +0.4% | -0.6% |
| Nov 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $150.02 | $147.50 | -1.7% | -1.8% | -0.3% | -1.8% | +0.5% | -0.9% |
| Nov 3 | JP Morgan | Maintains | Overweight → Overweight | — | $143.21 | $142.62 | -0.4% | -0.9% | +0.9% | +7.4% | +0.7% | -1.6% |
| Oct 30 | Truist | Maintains | Buy → Buy | — | $138.02 | $137.41 | -0.4% | +0.0% | +3.7% | -0.9% | +0.9% | +7.4% |
| Oct 29 | RBC Capital | Maintains | Outperform → Outperform | — | $147.38 | $140.00 | -5.0% | -6.4% | +0.0% | +3.7% | -0.9% | +0.9% |
| Oct 29 | Piper Sandler | Maintains | Overweight → Overweight | — | $147.38 | $140.00 | -5.0% | -6.4% | +0.0% | +3.7% | -0.9% | +0.9% |
| Oct 29 | Citigroup | Maintains | Buy → Buy | — | $147.38 | $140.00 | -5.0% | -6.4% | +0.0% | +3.7% | -0.9% | +0.9% |
| Oct 29 | Needham | Maintains | Buy → Buy | — | $147.38 | $140.00 | -5.0% | -6.4% | +0.0% | +3.7% | -0.9% | +0.9% |
| Oct 29 | Stifel | Maintains | Buy → Buy | — | $147.38 | $140.00 | -5.0% | -6.4% | +0.0% | +3.7% | -0.9% | +0.9% |
| Oct 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $147.38 | $140.00 | -5.0% | -6.4% | +0.0% | +3.7% | -0.9% | +0.9% |
| Oct 20 | Morgan Stanley | Maintains | Overweight → Overweight | — | $140.09 | $141.08 | +0.7% | +0.9% | +0.9% | -0.8% | +1.6% | +0.2% |
| Oct 9 | UBS | Maintains | Buy → Buy | — | $139.08 | $139.94 | +0.6% | -0.4% | -1.3% | +0.5% | -0.1% | +0.4% |
| Sep 22 | Needham | Maintains | Buy → Buy | — | $145.23 | $145.00 | -0.2% | +1.0% | -0.2% | +0.2% | -3.9% | +0.8% |
| Sep 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $140.40 | $140.76 | +0.3% | +2.6% | -0.2% | +0.3% | -2.0% | +1.7% |
| Sep 5 | RBC Capital | Maintains | Outperform → Outperform | — | $140.40 | $140.76 | +0.3% | +2.6% | -0.2% | +0.3% | -2.0% | +1.7% |
| Aug 6 | JP Morgan | Maintains | Overweight → Overweight | — | $128.39 | $127.79 | -0.5% | +0.0% | -2.2% | -0.5% | -0.8% | +4.0% |
| Aug 1 | Guggenheim | Maintains | Buy → Buy | — | $128.23 | $126.40 | -1.4% | +0.5% | -0.7% | +0.3% | +0.0% | -2.2% |
| Jul 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $136.76 | $137.10 | +0.2% | -6.2% | +0.5% | -0.7% | +0.3% | +0.0% |
| Jul 31 | Wedbush | Maintains | Outperform → Outperform | — | $136.76 | $137.10 | +0.2% | -6.2% | +0.5% | -0.7% | +0.3% | +0.0% |
| Jul 31 | Morgan Stanley | Maintains | Overweight → Overweight | — | $136.76 | $137.10 | +0.2% | -6.2% | +0.5% | -0.7% | +0.3% | +0.0% |
| Jul 31 | Baird | Maintains | Outperform → Outperform | — | $136.76 | $137.10 | +0.2% | -6.2% | +0.5% | -0.7% | +0.3% | +0.0% |
| Jul 31 | RBC Capital | Maintains | Outperform → Outperform | — | $136.76 | $137.10 | +0.2% | -6.2% | +0.5% | -0.7% | +0.3% | +0.0% |
| Jul 31 | JP Morgan | Maintains | Overweight → Overweight | — | $136.76 | $137.10 | +0.2% | -6.2% | +0.5% | -0.7% | +0.3% | +0.0% |
| Jul 31 | Stifel | Maintains | Buy → Buy | — | $136.76 | $137.10 | +0.2% | -6.2% | +0.5% | -0.7% | +0.3% | +0.0% |
| Jul 22 | Morgan Stanley | Maintains | Overweight → Overweight | — | $131.83 | $132.52 | +0.5% | +0.7% | +0.7% | -1.5% | +0.4% | +1.2% |
No insider trades available.
SC TO-T/A
! Medium
Soleno Therapeutics, Inc. -- Tender Offer Amendment
Neurochem Inc. (NBIX) is acquiring Soleno Therapeutics (SLNO) for $53 per share, representing a significant premium to recent trading prices.
Apr 29
SC TO-T
! Medium
Soleno Therapeutics, Inc. -- Tender Offer Amendment
Neurochem Inc. is acquiring Soleno Therapeutics for $53 per share through a tender offer, representing a significant premium for Soleno shareholders.
Apr 28
SC TO-T
!!! Very High
Soleno Therapeutics, Inc. -- Tender Offer
Neurochem Inc. is acquiring Soleno Therapeutics for $53 per share in cash, representing a significant premium for Soleno shareholders.
Apr 20
8-K
Unknown — 8-K Filing
Neurochem/Silence Therapeutics merger is proceeding with no financing risk and a guaranteed 20-day offer period, reducing deal uncertainty and supporting stock prices through closing.
Apr 6
8-K
Unknown — 8-K Filing
Neurocrine (NBIX) is being acquired by an unidentified purchaser in a financing-certain deal, with a tender offer launching within ten business days—providing clarity on deal certainty for shareholders.
Apr 6
8-K
Neurocrine Biosciences Inc -- 8-K Filing
Neurocrine Biosciences reported strong 2025 revenue growth of 22% to $2.83 billion, but guided 2026 INGREZZA sales flat to slightly down at $2.7-2.8 billion, signaling slowing momentum.
Feb 11
Data updated apr 26, 2026 2:20pm
· Source: massive.com